The molecule is the same. The format is the whole decision.
NAD+ has become one of the most requested longevity offerings in DTC telehealth.
Patients ask for it by name. They have seen it tied to energy, cellular repair, healthy aging, and recovery. Demand is real and growing.
Here is what most teams get wrong: they treat "NAD+" as a single product decision.
It is not.
NAD+ is the same coenzyme regardless of how it enters the body. But the delivery format changes almost everything that matters operationally:
- how strong the clinical evidence is
- how much of the dose is actually usable
- what it costs to deliver
- how well patients stick with it
- how it is sourced and regulated
- what your providers have to review
- what you can responsibly claim
A NAD+ program built around IV infusions is a completely different business than one built around oral precursors, even though the marketing word is the same.
This post compares the four formats DTC telehealth teams actually consider, so you can choose the right one for your program rather than defaulting to whatever is loudest in the market.
The four formats at a glance
| Format | What it is | Typical setting | Evidence for healthspan | Relative cost |
|---|---|---|---|---|
| IV infusion | NAD+ delivered intravenously over a long session | Clinic or in-home nurse visit | Weakest for anti-aging outcomes | Highest |
| Subcutaneous or IM injection | Compounded NAD+ self-injected or administered | At-home after training | Limited outcomes data | Moderate |
| Nasal spray | Compounded NAD+ delivered intranasally | At-home | Limited, format-specific data | Lower |
| Oral precursors (NMN, NR) | Capsules or tablets that raise NAD+ indirectly | At-home daily | Strongest target engagement data | Lowest |
The pattern to notice: the formats patients ask for most loudly (IV and injection) have the least outcomes evidence, while the format with the most data (oral precursors) gets the least hype.
That tension is the core of every NAD+ program decision.
What the evidence actually supports
Being precise here protects the brand and the patient.
Oral precursors have the most human data
NMN and NR are precursors. The body converts them toward NAD+.
Human studies consistently show these raise blood NAD+ levels and are generally well tolerated. NMN in the few-hundred-milligram range has been shown to raise NAD+ meaningfully over weeks, and NR has been studied across many trials at doses up to the low thousands of milligrams per day without serious safety signals.
The important caveat: raising a blood marker is target engagement, not a proven healthspan outcome. The downstream functional, metabolic, and vascular results across trials are mixed and often null. The biochemistry moves. The life-extension claim is not established.
IV and injectable NAD+ have the least outcomes data
There are no robust anti-aging or wellness outcomes trials for IV or intramuscular NAD+. There is no universally accepted dosing standard, no validated endpoint set, and limited long-term safety data specific to these formats.
That does not mean patients do not report feeling something. It means the evidence base does not support strong clinical claims, and your marketing has to reflect that.
Nasal and other compounded formats are format-specific
Compounded nasal NAD+ has even less format-specific published evidence. It exists primarily because it is easier and more comfortable than injection for some patients, not because it has a stronger data set.
The honest summary for operators:
- biochemical target engagement: reasonable for oral precursors
- proven healthspan outcomes: not established for any format
- IV and injectable: popular and premium-priced, but the least evidence-backed
Metabolic and Longevity
The group most adjacent to existing GLP-1 programs. Natural cross-sell candidates for an established metabolic patient base.
Often called 'exercise in a vial.' Research interest around metabolism, insulin sensitivity, and obesity-adjacent indications.
Most discussed in the longevity context, including telomere-related research and sleep regulation.
Format-by-format comparison for operators
IV infusion
- Bioavailability: High, delivered directly to the bloodstream
- Patient experience: Long sessions, can cause discomfort if infused quickly, needs a clinical setting or in-home nurse
- Adherence: Low frequency by nature, but high friction per session
- Cost to deliver: Highest, includes nursing time and setting
- Compliance: Compounded preparation, not FDA-approved for anti-aging, requires careful provider oversight
- Best for: Premium positioning, patients who want the most intensive experience, programs with clinical infrastructure
Subcutaneous or intramuscular injection
- Bioavailability: Good, bypasses the gut
- Patient experience: At-home self-injection after training, similar to insulin technique
- Adherence: Moderate, depends on comfort with needles and a clear schedule
- Cost to deliver: Moderate, no clinical session required
- Compliance: Compounded, provider review required, dosing discipline matters
- Best for: Patients who want injectable NAD+ without clinic visits, programs that can support at-home injection education
A practical dosing note: some clinicians cap subcutaneous NAD+ around a few hundred milligrams per week and titrate carefully, because higher or faster dosing tends to drive discomfort and offers no proven additional benefit. Your providers set the protocol, not the patient.
Nasal spray
- Bioavailability: Variable and less characterized than injection
- Patient experience: Easy, needle-free, comfortable
- Adherence: Higher, low friction encourages daily use
- Cost to deliver: Lower than injection
- Compliance: Compounded, provider review required
- Best for: Needle-averse patients, programs prioritizing comfort and adherence over maximal dose delivery
Oral precursors (NMN, NR)
- Bioavailability: Indirect, raises NAD+ through conversion rather than direct delivery
- Patient experience: A daily capsule, the easiest possible routine
- Adherence: Highest, fits existing supplement habits
- Cost to deliver: Lowest
- Compliance: Supplement pathway, not a compounded prescription (see the regulatory section)
- Best for: The widest patient base, entry-level longevity offerings, programs that want a low-friction recurring product
The regulatory picture changed in late 2025
This is the part that reshapes NAD+ program design in 2026.
Oral NMN is a supplement again
In December 2025, the FDA reversed its earlier position and confirmed that NMN can be lawfully marketed as a dietary supplement, with a pathway through the New Dietary Ingredient process. This overturned the 2022 stance that had pushed NMN into a gray zone.
For operators, that means oral NMN can be offered as a supplement product rather than a compounded prescription. It also means patent and quality questions matter, since not all NMN on the market is equal, and the EU still treats NMN under stricter novel-food rules.
Injectable, IV, and nasal NAD+ are compounded preparations
These formats are not FDA-approved drugs. They are compounded by licensed pharmacies for individual patients under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
That carries real obligations:
- a legitimate prescriber-patient relationship
- individualized prescriptions, not mass-market sale
- a compliant compounding pharmacy partner
- accurate, non-misleading patient communication
- no implication that a compounded product is FDA-approved
The compliance posture differs sharply by format. An oral supplement program and a compounded injectable program are governed by different rules, and conflating them is a common and avoidable mistake.
For choosing a pharmacy partner, see How to Choose a Compounding Pharmacy for Your Telehealth Program.
Matching format to patient
A strong program does not push every patient toward the highest-margin format. It routes by fit.
| Patient profile | Likely best format |
|---|---|
| New to longevity, wants low commitment | Oral precursor |
| Needle-averse but wants more than a pill | Nasal spray |
| Comfortable self-injecting, wants direct delivery | Subcutaneous injection |
| Wants the most intensive, premium experience | IV (if you have clinical infrastructure) |
| Cost-sensitive | Oral precursor |
| Adherence-challenged | Oral precursor or nasal, for the low friction |
| Already on a peptide or GLP-1 injection routine | Injection fits the existing habit |
This routing should happen in intake and provider review, not at a sales step. The patient expresses preference and context. The provider decides what is appropriate.
For how this fits a multi-compound program, see The Longevity Stack: Combining NAD+, Peptides, GLP-1, and Rapamycin in One DTC Program.
What changes in intake by format
Intake should capture more than "do you want NAD+."
Collect:
- which format the patient is asking about and why
- needle tolerance and self-injection comfort
- prior NAD+ or precursor use and response
- current supplements and medications
- relevant medical history and contraindications
- adherence patterns with daily routines
- cost sensitivity and willingness to commit
- goals (energy, recovery, healthy aging) stated in the patient's own words
This gives providers the context to route to the right format and to set honest expectations.
What changes in provider review by format
Provider review is not identical across formats.
- Oral precursors: lighter review, focused on suitability, interactions, and expectation setting
- Nasal: compounded review, dosing, contraindications
- Injection: compounded review plus injection-technique education and a dosing ceiling
- IV: the heaviest review, including setting, monitoring, and infusion rate guidance
Provider templates should differ by format so the chart reflects what was actually decided, including the format rationale and the dosing protocol.
What changes in patient education by format
Patients need different education depending on what they are taking.
- Oral: timing, consistency, what to realistically expect
- Nasal: administration technique, storage, frequency
- Injection: reconstitution if applicable, injection sites, technique, sharps disposal, how slowly to dose
- IV: what to expect during the session, why rate matters, aftercare
Education content should be format-specific. A single generic "NAD+ guide" leaves injection and IV patients underprepared.
Marketing NAD+ honestly
NAD+ marketing is under more scrutiny in 2026 because claims have outrun evidence.
A simple discipline:
- Defensible: describe NAD+ as a coenzyme involved in cellular energy and metabolic processes, note that levels decline with age, and explain what your program does
- Provisional: reference that oral precursors raise NAD+ levels in studies, framed as biochemical target engagement, not a healthspan promise
- Off-limits: anti-aging guarantees, disease-treatment claims, implying compounded NAD+ is FDA-approved, or presenting IV NAD+ as evidence-backed for longevity
The brands that overclaim will draw regulatory attention. The brands that explain the molecule honestly and let the program quality speak will hold trust longer.
For the broader claims discipline, see Trust Signals on Telehealth Landing Pages: Conversion Without Hype.
A format-selection checklist
Use this before launching or expanding a NAD+ offering.
Strategy
- Primary format chosen - Which format anchors the program, and why?
- Evidence posture documented - What the team will and will not claim by format.
- Patient routing logic - How intake and providers route to the right format.
- Premium vs accessible positioning - Where each format sits in pricing.
Compliance
- Supplement vs compounded line drawn - Oral precursors vs compounded formats handled separately.
- Pharmacy partner verified - 503A or 503B fit for compounded formats.
- NMN sourcing and quality - Purity and patent considerations for oral.
- Claims reviewed - Marketing checked against the evidence by format.
- Prescriber relationship - Legitimate individualized prescriptions for compounded formats.
Clinical and operational
- Dosing protocols set - Per-format dosing and ceilings defined by providers.
- Intake captures format context - Needle tolerance, history, goals.
- Provider templates by format - Review reflects the format decision.
- Format-specific education - Separate patient guides for oral, nasal, injection, IV.
- Adherence support - Reminders and check-ins matched to the format.
Metrics to track
| Metric | Why it matters |
|---|---|
| Format mix of new patients | Where demand actually lands |
| Adherence by format | Whether patients sustain the routine |
| Refund rate by format | Whether expectations matched experience |
| Provider review time by format | Capacity planning |
| Reorder rate by format | Real retention signal |
| Support tickets by format | Education gaps |
| Conversion by format and price | Which offering sustains the program |
For the leadership dashboard, see Weekly Telehealth Ops Dashboard: 12 Metrics Leadership Should Review.
Common mistakes
Treating NAD+ as one product
The format is the decision. Build separate workflows for oral, nasal, injection, and IV.
Pushing IV because it has the highest margin
IV has the least evidence and the highest friction. Lead with patient fit, not margin.
Conflating supplement and compounded compliance
Oral NMN and compounded injectable NAD+ are governed by different rules. Keep them separate.
Letting patients self-select dose
Especially for injection and IV. Providers set the protocol and the ceiling.
One generic education guide
Each format needs its own instructions, particularly the injectable and IV formats.
Overclaiming on outcomes
Biochemistry is not healthspan. Claim what the evidence supports and no more.
Final takeaways
NAD+ is one molecule and four very different businesses.
The teams that build NAD+ programs well in 2026 will:
- choose the format by patient fit and evidence, not by hype or margin
- recognize oral precursors have the strongest data and the lowest friction
- treat IV and injectable NAD+ as premium experiences with limited outcomes evidence
- separate the supplement pathway for oral NMN from the compounded pathway for injectable, nasal, and IV
- route patients to the right format in intake and provider review
- set dosing protocols and ceilings at the provider level
- give format-specific education and adherence support
- market the molecule honestly and avoid outcome guarantees
The word on the landing page can say NAD+.
The program underneath has to know exactly which NAD+ it is selling, to whom, with what evidence, and under which rules.
That clarity is what turns a trendy molecule into a durable longevity program.